SCHEDULED MAINTENANCE
Nitric oxide inhibition, antioxidant, and antitumour activities of novel copper(ii) bis-benzimidazole diamide nanocoordination complexes†
Abstract
Novel copper(II) nanocoordination complexes [LCuCl]Cl C1, [LCu(SCN)]SCN C2, and [LCu(NO3)]NO3C3 capped by bis-benzimidazole diamide ligand N1,N5-bis{(1H-benzo[d]imidazole-2-yl)methyl}glutarimide L were synthesized and characterized by spectroscopic methods viz. transmission electron microscopy (5–100 nm), dynamic light scattering, elemental analysis, EPR, and infrared spectroscopy. These complexes were also tested for their ability to inhibit nitric oxide release during culture. Lipopolysaccharide-induced superoxide production decreased most significantly for complex C2. Nanocoordination complex C2 also showed the most significant in vitro cytotoxicity against HeLa human cervical cancer cells, MCF-7 breast cancer cells, and U-87 glioblastoma cells, ranging from 50 μg ml−1 to 500 μg ml−1. In vivo study revealed an increase in body weight (11.5 g) for the tumour control groups, whereas in the case of the mouse groups treated with test sample C3, the difference in body weight as compared to the control was approximately 4.7 g. In further studies, it decreased to 2.2 g and 0.6 g in the case of mouse groups treated with nanocoordination complexes C1 and C2, respectively. The mean mouse survival time was 21 days, which increased to 100, 120, and 170 days for C3, C1, and C2, respectively.
Please wait while we load your content...
